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Background: Ras association domain family 1A gene (RASSFlA) is a candidate suppressor gene, Lack of RASSF1A
expression was found in lung cancer. High DNA methylation at the promoter region is the main reason for
inactivating RASSF1A transcription.
Methods: In this study, we examined RASSF1A’s methylation status and its mRNA expression level between
non-small cell lung cancer cell line A549 and anti-Cisplatin cell strain A549DDP, Furthermore, methylation of
A549DDP was reversed by treatment of 5-Aza-2′ - deoxycytidine (5-Aza-cdR),a DNA methyltransferase inhibitor.
Results: We found that RASSF1A’s methylation status and its mRNA expression were obvious differences between
A549 and A549DDP. 5-Aza-CdR treatment remarkablly reduced cell vability of A549DDP. Moreover, 5-Aza-CdR
treatment induced A549DDP cell apoptosis in a dose dependent manner with declining cell percentage in S and
G2/M stage, and increasing proportion in G0/G1 stage. Cell motility was blocked in G0/G1 stage. All of A549DDP
cells showed unmethylated expression, its high methylation status was reversed in a dose-dependent manner
within a certain range.
Conclusions: The abnormal gene methylation status of RASSF1A is a molecular biomarker in lung cancer diagnosis,
treatment and prognosis.
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Lung cancer is one of the most common malignant tu-
mors with highest incidence and morbidity [1,2]. Late de-
tection is a major contributor to these high mortality rates
[3]. Most patients are already at the late stage of lung can-
cer when they are diagnosed. Cisplatin [4] is the first-line
chemotherapy drug, used in the late stage of lung cancer.
However, cisplatin and other drugs are not efficient
chemotherapy in non-small cell lung cancer (NSCLC). It
is the most urgent to conquer the drug-resistance of
NSCLC in cancer therapy.
Recent studies have shown that the inactivation of
tumor-suppressor genes plays an important role in the
pathogenesis and chemotherapy sensitiveness of lung can-
cer [5]. Ras association domain family 1A gene (RASSFlA)* Correspondence: lishijun@dl.cn
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stated.is a candidate suppressor gene [6], which is localized at
3p21.3, coding a group of RAS protein. Homozygote and
heterozygote loss of RASSF1A was found in more than
90% of small cell lung cancer and in 50-80% of non-small
cell lung cancer [7,8]. High DNA methylation at the pro-
moter region is the main reason [9], especially in CpG
islands. Low methylation of DNA can make chromosome
instability [10], such as chromosome breakage, transloca-
tion and lost, and proto-oncogene activation; High methy-
lation of DNA promoter region CpG islands can make the
tumor suppressor gene inactivation [11,12]. Methylation
status is a biomarker, but it can be reversed by methyl-
transferase inhibitor, such as 5 - Aza – CdR [13]. In this
study, we studied the abnormal gene methylation status of
RASSF1A in NSCLC cell line A549 and anti-Cisplatin cell
strain A549DDP and suggested that methyaltion of
RASSF1A is a molecular biomarker in cancer diagnosis,
treatment and prognosis.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 2 RASSF1A gene’s expression detected by RT-PCR. Up
Lane: RASSF1A (331 bp); Down Lane: β–actin (271 bp), Lane 1: A549
Mengxi et al. Cancer Cell International 2013, 13:91 Page 2 of 5
http://www.cancerci.com/content/13/1/91Results
RASSF1A methylation in lung cancer cells
To investigate the different status of RASSF1A DNA
methylation in lung cancer cells, we examined DNA
methylation of RASSF1A in the Cisplatin-resistant cell
strain A549DDP and A549 lung cancer cells by MSP.
We found that RASSF1A gene was mostly methylated in
Cisplatin-resistant cell strain A549DDP; but, mostly
unmethylated in A549 cell line (Figure 1).cell; Lane 2: A549DDP cell; Lane 3: A549DDP 5 μmol/L group;
Lane 4: A549DDP 10 μmol/L group; Lane 5: A549DDP
20 μmol/L group.RASSF1A mRNA expressionin in lung cancer cells
To investigate the different of RASSF1A gene’s expression
between A549DDP and A549 lung cancer cells,we used
RT-PCR to detect it. We found that RASSF1A gene’s ex-
pression in A549 cell line was clearly higher than
A549DDP. In these two kinds of cells, the RASSF1A
methylation status was tended to vary inversely with its
mRNA’s transcriptional level (Figure 2). We hypothe-
sized that DNA methylation can cause gene expression
to cut down.5 -Aza -CdR can effect RASSF1A gene methylation status
and gene expression
We found that RASSF1A’s methylation status and its
mRNA’s expression were obvious differences between
A549 and A549DDP. In A549DDP group, RASSF1A gene
was highly methylation expression and little mRNA
expression. Wether such status can be reversed by
methyltransferase inhibitor, we added different concentra-
tion of 5 - Aza - cdR to A549DDP cells. After training
48 hrs, we found that RASSF1A genes showed unmethyl-
ated states and the mRNA expression increased in all ex-
perimental groups. Used optical density ratio of β-actin
gene, when the 5-Aza-CdR concentation was 0 μmol/L,
5 μmol/L, 10 μmol/L, 20 μmol/L, the relative expression
level were 0.06 ± 0.02, 0.22 ± 0.11, 0.36 ± 0.16, 0.54 ± 0.15.
The RASSF1A mRNA expression was raised in eachFigure 1 MSP detected RASSF1A’s methylation status before
and after adding to 5 -Aza –CdR in different concentration.
Lane M: methylated stripe (119 bp); Lane U: unmethylated stripe
(125 bp); Lane 1: A549DDP cell; Lane 2: A549 cell; Lane 3: A549DDP
5 μmol/L group; Lane 4: A549DDP 10 μmol/L group; Lane 5:
A549DDP 20 μmol/L group.group, the difference had statistics significance (P < 0.05)
(Figures 1 and 2).
Detecting A549DDP cell inhibitory situation by MTT assay
To investigate the different cell inhibitory status between
lung cancer cells, we examined them by MTT assay. We
found that A549DDP cells showed a remarkable inhibition
action after 48 hrs treatment of 5-Aza-CdR. The inhibition
rate increased with the increase of drug dosage in a dose
dependent manner. The inhibition rates were 8.4%, 18.9%,
27.8%, when drug dosage were 5 μmol/L, 10 μmol/L,
20 μmol/L,which was statistically significant by compari-
son with control group (P < 0.05) (Figure 3). We hypothe-
sized that 5-Aza-CdR treatment remarkablly rduced cell
vability of A549DDP.
Cell apoptosis and cell cycle detected by flow cytometry
To investigate the different cell apoptosis and cell cycle
between lung cancer cells, we examined them by flow
cytometry. We found that after 48 hrs intervention of
5-Aza-CdR, A549DDP cells apoptosis increasing, and go
with the increase of drug dosage in a dose dependent
manner. When concentration were 0 μmol/L, 5 μmol/L,
10 μmol/L, 20 μmol/L, the apoptosis rate were 6.70%,
8.56%, 17.84%, 38.91%. The results of 10 μmol/L andFigure 3 MTT assay detected A549DDP cell inhibitory situation
after 48 hrs intervention of 5-Aza-CdR in different concentrations.
Table 1 Cell cycle detected by flow cytometry
Group G0/G1 S G2/M
Control 60.94 ± 1.73 34.12 ± 1.52 4.94 ± 0.27
5 μmol/L 62.79 ± 2.21 31.82 ± 1.77 5.39 ± 0.36
10 μmol/L 69.35 ± 1.46 26.41 ± 1.67 4.24 ± 0.83
20 μmol/L 79.98 ± 2.08 18.07 ± 1.03 1.95 ± 0.53
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son with control group (P < 0.05), but 5 μmol/L group
had no statistically signification (P > 0.05). (Figure 4). At
the same time, cell percentage in S and G2/M declined,
and proportion in G0/G1 stage increased. Cell motility
was blocked in G0/G1 stage (Table 1).
Discussion
RASSF1A is a tumor suppressor gene in widely research,
that participation in a variety of biological events, such
as cell growth, differentiation and apoptosis, plays an
important inbibitional effect in tumor growth process,
RASSF1A has also been associated with stabilization of
microtubules and has been shown to influence cell mo-
tility and genomic stability [14-16]. RASSF1A promoter
methylation states in small cell lung cancer, non small
cell lung cancer and breast cancer cell lines were 100%,
63% and 64% respectively,while the nomal lung tissue is
none, and higher degree in poorly differentiated tumors,
but lower in well differentiated tumors [17]. Dammann
[18] studied eight pancreatic cancer cell lines found that
RASSF1A gene promoter regions methylated in almost
seven lines, five lines were completely methylated, two
were partly methylated. So DNA methylation can result
in tumor occurrence, development and drug-resistant, it
has become a new research direction.
In the study, RASSF1A mainly unmethylation status in
A549 cells, but high methylation status in A549DDP; And
its mRNA expression of A549 was obviously higher than
that of A549DDP. The relationships between them had in-
versely proportional. It was showed that high promoter
methylation status of RASSF1A might be an important
foundation to reduce gene transcription activity, moreover
involved in drug resistance in non-small cell lung cancer.
5 - Aza - CdR can make RASSF1A gene to demethylate
and gene expression again or enhance. Further showed that
it also significantly inhibited A549DDP cell proliferationFigure 4 Cell apoptosis detected by flow cytometry with FITC and PI
(FITC+/PI+); LR shows apoptotic cells (FITC +/PI-); a: control group (0 μmol
d: 20 μmol/L 5-Aza-CdR.and increased cell apoptosis rate, cell cycle arrest in
G0/G1 phase.
As DNA methyltransferase inhibitor, 5 - Aza - CdR [19]
mainly by phosphorylated action, and do not affect DNA
synthesis, restore normal function, which is very import-
ant to cell differentiation and proliferation. Mostly import-
ant, 5 - Aza - CdR is insensitive to non-proliferative cells.
The Federal Drug Administration has approved DNA
methyltransferase inhibitors for the treatment of myelo-
dysplastic syndrome [20]. Drugs of this class have also
been used successfully in other hematological malignan-
cies [21]. More recently, pre-clinical and clinical data
have demonstrated that these inhibitors can be used to
reduce the malignant potential of solid tumors as well
[22]. But 5 - Aza - CdR is not stable and has toxicity in
aqueous solution. The demethylation is lack of specific
target. It is worth to further discussing that its clinical
efficacy, tolerability in vivo and the best compatibility
dose, if it can be used in lung cancer treatment.Conclusions
Taken together, we demonstrate that RASSF1A’s methy-
lation status was reversed by treatment of 5-Aza-2′-
deoxycytidine. Moreover, cell apoptosis and growth
were changed. Cell motility was blocked in G0/G1 stage.
RASSF1A’s methylation status may be a new biology
marker and gene therapy target in lung cancer.staining. LL shows living cells (FITC-/PI-); UR shows necrotic cells
/L 5-Aza-CdR), b: 5 μmol/L 5-Aza-CdR, c: 10 μmol/L 5-Aza-CdR,
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Cell culture
Human non-small lung cancer cell line A549 obtained
from the First Affiliated Hospital of Dalian Medical
University (Liaoning, China). Human anti-Cisplatin non-
small lung cancer cell strain A549DDP Purchased in
Runcheng biotechnology company (Nanjing, China). A549
and A549DDP cells were cultured in RPMI-1640 medium
(Invitrogen, USA) containing 10% fetal bovine serum
(Gibcobrl, USA), at 37°C in a humidified incubator con-
taining 5% CO2. Added cisplatin (Jiangsu Haosen, China)
to A549DDP medium and the final concentration was
2 μg/ml; The cells were passaged once or twice every
week. Cells at algorism growth phase were used in follow-
ing experiments.
Methylation-specific PCR(MSP)
Both cells were collected and washed with phosphate buff-
ered saline (PBS). Adjusted cell number to 2 × 103. DNA
was extracted from the cells using EZ DNA Methylation-
Direct Kit™ (ZYMO, USA) according to the manufacturer’s
protocol. Reaction system content 10 μl Tag PCR Master
Mix, 1 μl Primer1, 1 μl Primer2, add ddH2O to 20 μl. Up-
stream and downstream primers for RASSF1A-M (meth-
ylated stripe, 119 bp) were 5′-GTGTTAACGCGTTGCG
TATC-3′ and 5′-AACCCCGCGAACTAAAAACGA-3′,
respectively. Upstream and downstream primers for
RASSF1A-U (unmethylated stripe, 125 bp) were 5′-
TTTGGTTGGAGTGTGTTAATGTG-3′ and 5′-CAAA
CCCCACAAACTAAAAACAA-3′. The conditions were
94°C for 5 min, followed by 35 cycles of 94°C for 30s, 55°C
(RASSF1A-M) or 60°C (RASSF1A-U)for 30 s, and 72°C
for 30s and a final extension at 72°C for 10 min. 10 μl
PCR products were separated on the 2% agarose gel and
viewed by ethidium bromide (EB) staining. By using
tanon image analysis software, scaned optical density of
RASSF1A and β-actin gene in electrophoresis image, in-
dicating with both absorbance ratios.
RT-PCR
Both cells were collected and washed by phosphate buff-
ered saline (PBS). Total RNA was extracted from the cells
using RNAiso reagent (Takara, Dalian, China) 1 μl total
RNA were amplified by using PrimeScript™ One Step RT-
PCR Kit Ver.2 (Takara, Dalian, China), reaction system
was 50 μl, according to the manufacturer’s protocol. Up-
stream and downstream primers for RASSF1A (331 bp)
were 5′–ACTTGCGGAAGCTGTTGGA-3′ and 5′-CG
CTGCAGGATACG TAGGAA-3′, respectively. Upstream
and downstream primers for β-actin (271 bp) were 5′-
CTACAATGAGCTGCGTGTGGC-3′ and5′-CAGGTCC
AGACGCAGGATGGC-3′, respectively. The conditions
were 50°C for 30 min, 94°C for 2 min, followed by 30 cycles
of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. 10 μlPCR products were separated on the 2% agarose gel and
viewed by ethidium bromide (EB) staining. These data
were acquired with Tianneng software too.
A549DDP cells treatment by 5 - Aza – cdR in different
concentration
A549DDP cells in logarithmic phase with cell number was
(1.5-2) × 104/ml were incubated in a 96-well plate, each
hole for 200 μl, at 37°C in a humidified incubator
containing 5% CO2 to continue training. Removed the nu-
trient solution after 24 hrs, and then, added to different
concentration of 5 - Aza - cdR (5 μ mol/l, 10 μ mol/l, and
20 μ mol/l) respectively, final volume was 200 μl/well each
hole. The control group was the holes that without adding
drug. Each group had four Repeat holes, further training
at 37°C for 48 hrs.
5-Aza-CdR treatment effecting RASSF1A’s methylation
status and its mRNA’s expression
Extracting DNA of above drug treated cells for MSP, total
RNA for RT-PCR, to detect the change of RASSF1A’s
methylation status and mRNA’s expression level after
adding 5 - Aza - CdR. The conditions and methods follow
the former.
MTT assay
The above A549DDP cells in each group were added to
5 mg/ml MTT (20 μl/well) and further incubated at 37°C
for 4 hrs, then added with DMSO (150 μl/well) and incu-
bated for 10 min. A592 was determined by a 96-well mi-
crotitre plate reader. According to the following formula,
all experiments were performed in triplicate.
Cell inhibitory rate %ð Þ
¼ 1–ODof test group=OD of control groupð Þ
 100%:
Flow cytometry
A549DDP cells above were collected, washed three times
with PBS and added to 1 ml ethanol (70%), fixed 2 hrs at
4°C. Washed with PBS, and then, removed supernatant
after centrifugating. For detecting cell cycle, added with
0.5 ml propidium iodide (PI), then incubated at 37°C in
dark for 30 min; For detecting cell apoptosis rate, added
with 500 μl Annexin binding buffer, 5 μl Annexin V-FITC,
and 5 μl propidium iodide (PI), then incubated at room
temperature in dark for 15 min. The cell apoptosis and
cell cycle were determined by flow cytometry (BD, USA)
and analyzed with Cell Quest software.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 software
(SPSS Incorporation, Chicago, USA). Data are expressed
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ANOVA. P < 0.05 was considered statistics significance.
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